BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, Yoshida S, Nishimura M, Haruno M, Ishikura S. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425-433. [PMID: 12957254 DOI: 10.1016/s0360-3016(03)00585-6] [Cited by in Crossref: 154] [Cited by in F6Publishing: 48] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Li Y, Chen Y, Jiang X, Yu H, Yan S, Hashmi MF. Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy. Contrast Media & Molecular Imaging 2022;2022:1-6. [DOI: 10.1155/2022/3678441] [Reference Citation Analysis]
2 Sakaguchi M, Maebayashi T, Aizawa T, Ishibashi N, Okada M. Association between unintentional splenic radiation and lymphopenia and high neutrophil/lymphocyte ratio after radiotherapy in patients with esophageal cancer. Transl Cancer Res 2021;10:5076-84. [PMID: 35116359 DOI: 10.21037/tcr-21-1765] [Reference Citation Analysis]
3 Yang LT, Zhou L, Chen L, Liang SX, Huang JQ, Zhu XD. Establishment and Verification of a Prediction Model for Symptomatic Radiation Pneumonitis in Patients with Esophageal Cancer Receiving Radiotherapy. Med Sci Monit 2021;27:e930515. [PMID: 33953150 DOI: 10.12659/MSM.930515] [Reference Citation Analysis]
4 Thakur B, Devkota M, Chaudhary M. Management of Locally Advanced Esophageal Cancer. JNMA J Nepal Med Assoc 2021;59:409-16. [PMID: 34508544 DOI: 10.31729/jnma.4299] [Reference Citation Analysis]
5 Takeuchi H. Will definitive chemoradiotherapy be a new normal for patients with resectable locally advanced esophageal cancer? Esophagus 2020;17:363-4. [PMID: 32886211 DOI: 10.1007/s10388-020-00780-3] [Reference Citation Analysis]
6 Ishikura S, Kondo T, Murai T, Ozawa Y, Yanagi T, Sugie C, Miyakawa A, Shibamoto Y. Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease. J Radiat Res 2020;61:464-9. [PMID: 32249307 DOI: 10.1093/jrr/rraa008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Udagawa H. Past, present, and future of three-field lymphadenectomy for thoracic esophageal cancer. Ann Gastroenterol Surg 2020;4:324-30. [PMID: 32724875 DOI: 10.1002/ags3.12338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Taniyama Y, Sakurai T, Hikage M, Okamoto H, Sato C, Takaya K, Unno M, Kamei T. How does presurgical chemotherapy influence the efficiency of treatment for esophageal cancer recurrence after curative esophagectomy? Thorac Cancer 2019;10:769-74. [PMID: 30756477 DOI: 10.1111/1759-7714.12996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 34.5] [Reference Citation Analysis]
10 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25-43. [PMID: 30171414 DOI: 10.1007/s10388-018-0642-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 29.3] [Reference Citation Analysis]
11 Ma MW, Gao XS, Gu XB, Xie M, Cui M, Zhang M, Liu L, Yin H, Chen LQ. The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma. World J Surg Oncol 2018;16:172. [PMID: 30119684 DOI: 10.1186/s12957-018-1470-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
12 Chen H, Zhou L, Yang Y, Yang L, Chen L. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma. Med Sci Monit 2018;24:4183-91. [PMID: 29915168 DOI: 10.12659/MSM.910326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K, Moriya S, Tachibana H, Nakamura N, Kojima T, Akimoto T. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2018;13:23. [PMID: 29426342 DOI: 10.1186/s13014-018-0966-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
14 Li X, Zhao L, Zhang W, Yang C, Lian Z, Wang S, Liu N, Pang Q, Wang P, Yu J. Prognostic value of supraclavicular nodes and upper abdominal nodes metastasis after definitive chemoradiotherapy for patients with thoracic esophageal squamous cell carcinoma. Oncotarget 2017;8:65171-85. [PMID: 29029421 DOI: 10.18632/oncotarget.18015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Kumaran D, John S, Isiah R, Das S. Management of Locally Advanced Carcinoma Oesophagus with Radiation/Chemoradiation: Single Institute Experience. J Gastrointest Cancer 2016;47:313-7. [PMID: 27146042 DOI: 10.1007/s12029-016-9825-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg 2016;22:275-83. [PMID: 27384595 DOI: 10.5761/atcs.ra.16-00111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
17 Hori M, Someya M, Matsumoto Y, Nakata K, Kitagawa M, Hasegawa T, Tsuchiya T, Fukushima Y, Gocho T, Sato Y, Ohnuma H, Kato J, Sugita S, Hasegawa T, Sakata KI. Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy. Med Mol Morphol 2017;50:25-33. [PMID: 27338590 DOI: 10.1007/s00795-016-0144-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
18 Nomura M, Oze I, Kodaira T, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Tachibana H, Uemura N, Tajika M, Niwa Y, Muto M, Muro K. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. Int J Clin Oncol 2016;21:890-8. [PMID: 26980212 DOI: 10.1007/s10147-016-0963-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
19 Umezawa R, Jingu K, Matsushita H, Sugawara T, Kubozono M, Yamamoto T, Ishikawa Y, Kozumi M, Takahashi N, Katagiri Y, Kadoya N, Takeda K, Ariga H, Nemoto K, Yamada S. Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols. BMC Cancer 2015;15:813. [PMID: 26506988 DOI: 10.1186/s12885-015-1836-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
20 Yamashita H, Takenaka R, Omori M, Imae T, Okuma K, Ohtomo K, Nakagawa K. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study. Radiat Oncol 2015;10:171. [PMID: 26269033 DOI: 10.1186/s13014-015-0482-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
21 Nishimura Y, Jingu K, Itasaka S, Negoro Y, Murakami Y, Karasawa K, Kawaguchi G, Isohashi F, Kobayashi M, Itoh Y, Ariga T. Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG). Int J Clin Oncol 2016;21:88-94. [PMID: 26178368 DOI: 10.1007/s10147-015-0872-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
22 Okamoto H, Fujishima F, Kamei T, Nakamura Y, Ozawa Y, Miyata G, Nakano T, Katsura K, Abe S, Taniyama Y, Sakurai T, Teshima J, Hikage M, Sasano H, Ohuchi N. Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy. BMC Cancer 2015;15:208. [PMID: 25880782 DOI: 10.1186/s12885-015-1222-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
23 Kajiura S, Hosokawa A, Yoshita H, Ueda A, Ando T, Fujinami H, Nishikawa J, Ogawa K, Sugiyama T. Preventive effect of R ikkunshito, a traditional J apanese medicine, on chemotherapy‐induced nausea and vomiting with cisplatin: C ase series. Traditional & Kampo Medicine 2015;2:8-13. [DOI: 10.1002/tkm2.1012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Wakita A, Motoyama S, Sato Y, Koyota S, Usami S, Yoshino K, Sasaki T, Imai K, Saito H, Minamiya Y. REG Iα activates c-Jun through MAPK pathways to enhance the radiosensitivity of squamous esophageal cancer cells. Tumour Biol 2015;36:5249-54. [PMID: 25656613 DOI: 10.1007/s13277-015-3183-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
25 Hayashi K, Fujiwara Y, Nomura M, Kamata M, Kojima H, Kohzai M, Sumita K, Tanigawa N. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br J Radiol 2015;88:20140168. [PMID: 25429644 DOI: 10.1259/bjr.20140168] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
26 Hofstetter WL. Salvage esophagectomy. J Thorac Dis 2014;6 Suppl 3:S341-9. [PMID: 24876940 DOI: 10.3978/j.issn.2072-1439.2014.03.29] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
27 Matono S, Fujita H, Tanaka T, Mori N, Nagano T, Nishimura K, Hino H, Shirouzu K, Eto H, Ogo E, Yanagawa T. Salvage lymphadenectomy without esophagectomy is an option for recurrent or residual lymph nodes after definitive chemoradiotherapy for esophageal cancer. Esophagus 2014;11:197-203. [DOI: 10.1007/s10388-014-0430-z] [Cited by in Crossref: 7] [Article Influence: 0.9] [Reference Citation Analysis]
28 Gao Z, Meng X, Mu D, Sun X, Yu J. Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy. Oncol Lett 2014;7:1118-22. [PMID: 24944678 DOI: 10.3892/ol.2014.1881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
29 Fujita H. History of lymphadenectomy for esophageal cancer and the future prospects for esophageal cancer surgery. Surg Today 2015;45:140-9. [PMID: 24519395 DOI: 10.1007/s00595-014-0841-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
30 Yan H, Wang R, Jiang S, Zhu K, Feng R, Xu X, Meng X. NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus. Med Oncol 2014;31:796. [PMID: 24307347 DOI: 10.1007/s12032-013-0796-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
31 Shirai K, Tamaki Y, Kitamoto Y, Murata K, Satoh Y, Higuchi K, Ishikawa H, Nonaka T, Takahashi T, Nakano T. Prognosis was not deteriorated by multiple primary cancers in esophageal cancer patients treated by radiotherapy. J Radiat Res. 2013;54:706-711. [PMID: 23381956 DOI: 10.1093/jrr/rrt002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
32 Xu Y, Sheng L, Mao W. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action. Oncol Lett. 2013;5:19-24. [PMID: 23255886 DOI: 10.3892/ol.2012.994] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
33 Motoyama S, Ishiyama K, Maruyama K, Narita K, Minamiya Y, Ogawa J. Estimating the need for neck lymphadenectomy in submucosal esophageal cancer using superparamagnetic iron oxide-enhanced magnetic resonance imaging: clinical validation study. World J Surg 2012;36:83-9. [PMID: 22015919 DOI: 10.1007/s00268-011-1322-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
34 Kozu Y, Sato H, Tsubosa Y, Ogawa H, Yasui H, Kondo H. Surgical treatment for pulmonary metastases from esophageal carcinoma after definitive chemoradiotherapy: experience from a single institution. J Cardiothorac Surg. 2011;6:135. [PMID: 21992542 DOI: 10.1186/1749-8090-6-135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ishihara R, Yamamoto S, Iishi H, Nagai K, Matui F, Kawada N, Ohta T, Kanzaki H, Hanafusa M, Hanaoka N, Takeuchi Y, Higashino K, Uedo N, Sugimoto N, Kawaguchi Y, Nishiyama K, Motoori M, Yano M, Hosoki T. Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol 2012;17:225-32. [PMID: 21735356 DOI: 10.1007/s10147-011-0278-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
36 Sanuki N, Ishikura S, Shinoda M, Ito Y, Hayakawa K, Ando N. Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303. Int J Clin Oncol 2012;17:105-11. [PMID: 21667354 DOI: 10.1007/s10147-011-0264-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
37 Nishimura Y, Koike R, Ogawa K, Sasamoto R, Murakami Y, Itoh Y, Negoro Y, Itasaka S, Sakayauchi T, Tamamoto T. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey. Int J Clin Oncol. 2012;17:48-54. [PMID: 21607829 DOI: 10.1007/s10147-011-0254-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
38 Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy. Oncology 2010;79:363-9. [PMID: 21430405 DOI: 10.1159/000322498] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Yi Y, Li B, Sun H, Zhang Z, Gong H, Li H, Huang W, Wang Z. Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Tumour Biol. 2010;31:333-340. [PMID: 20490963 DOI: 10.1007/s13277-010-0041-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
40 Takeuchi H, Saikawa Y, Oyama T, Ozawa S, Suda K, Wada N, Takahashi T, Nakamura R, Shigematsu N, Ando N, Kitajima M, Kitagawa Y. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg 2010;34:277-84. [PMID: 20033687 DOI: 10.1007/s00268-009-0331-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
41 Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Kadoyama K, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int J Med Sci 2010;7:48-54. [PMID: 20151048 DOI: 10.7150/ijms.7.48] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
42 Motoyama S, Maruyama K, Sato Y, Usami S, Nakatsu T, Saito H, Minamiya Y, Ogawa J. Status of involved lymph nodes and direction of metastatic lymphatic flow between submucosal and t2-4 thoracic squamous cell esophageal cancers. World J Surg 2009;33:512-7. [PMID: 19009319 DOI: 10.1007/s00268-008-9781-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
43 Abrams JA, Buono DL, Strauss J, McBride RB, Hershman DL, Neugut AI. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer. 2009;115:4924-4933. [PMID: 19637343 DOI: 10.1002/cncr.24536] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
44 Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M. Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. BMC Cancer 2009;9:408. [PMID: 19930599 DOI: 10.1186/1471-2407-9-408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
45 Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2009;6:305-11. [PMID: 19834547 DOI: 10.7150/ijms.6.305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
46 Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 2009;61:388-401. [PMID: 19135108 DOI: 10.1016/j.addr.2008.10.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
47 Tachimori Y. Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2009;57:71-8. [PMID: 19214447 DOI: 10.1007/s11748-008-0337-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
48 Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Hasuike N, Inui T, Yamaguchi Y. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum. Int J Clin Oncol. 2008;13:150-155. [PMID: 18463960 DOI: 10.1007/s10147-007-0738-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
49 Ishii H, Sato H, Tsubosa Y, Kondo H. Treatment of double carcinoma of the esophagus and lung. Gen Thorac Cardiovasc Surg. 2008;56:126-130. [PMID: 18340512 DOI: 10.1007/s11748-007-0200-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
50 Kogo M, Suzuki A, Kaneko K, Yoneyama K, Imawari M, Kiuchi Y. Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer. Dig Dis Sci 2008;53:2415-21. [PMID: 18256935 DOI: 10.1007/s10620-007-0149-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
51 Nishimura M, Daiko H, Yoshida J, Nagai K. Salvage esophagectomy following definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2007;55:461-4; discussion 464-5. [PMID: 18049854 DOI: 10.1007/s11748-007-0157-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
52 Sasamoto R, Tsuchida E, Sugita T, Matsumoto Y, Abe E, Sasai K. Risk factors for enlargement of cardiac silhouette on chest radiography after radiotherapy for esophageal cancer. Radiat Med 2006;24:431-7. [PMID: 16958424 DOI: 10.1007/s11604-006-0050-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
53 Nakamura M, Kido Y, Hosoya Y, Yano M, Nagai H, Monden M. Postoperative gastrointestinal dysfunction after 2-field versus 3-field lymph node dissection in patients with esophageal cancer. Surg Today. 2007;37:379-382. [PMID: 17468818 DOI: 10.1007/s00595-006-3413-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
54 Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 2006;11:454-60. [PMID: 17180514 DOI: 10.1007/s10147-006-0610-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
55 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]